A Novel Synthetic Biology Platform for Controlling Gene Expression

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

A method for controlling gene expression using a novel phage-based transcription factor-peptide system.


Background and Unmet Need

A fundamental challenge of synthetic biology and its clinical applications is the capability to control gene expression. Presently, gene expression systems for research and industry have several limitations, such as a small number of available systems, inconsistent behavior among systems, lack of sufficient dynamic range of expression, and the requirement for high concentrations of a signaling molecule to induce/repress a gene. Consequently, there is a strong need for a better and diverse array of gene expression systems.

The Solution

team of Prof. Sorek at the Weizmann Institute of Science (WIS) has made the paradigm – shifting discovery that bacteriophages have a quorum sensing system, similar to that found in bacteria. The novel system, named Arbitrium by the Sorek team, communicates to said phages residing within bacteria, whether a lytic or lysogenic cycle is to be entered. Arbitrium system can be harnessed to a wide range of synthetic-biology and biotechnological applications.

Technology Essence

Phages can infect bacteria either in a lytic cycle, which lyses the bacterial wall, or in a lysogenic cycle in which the phage genome integrates into the bacterial genome. The research team of Prof. Sorek discovered the novel Arbitrium communication system that enables lytic or lysogenic cycle (Fig. A). The Arbitrium system functions on the basis of three genes, aimR, aimP, and aimX. AimR is a dimeric receptor that binds and activates the transcription of gene aimX, whereby AimX inhibits lysogeny leading to lysis (Fig. B). AimP is a six amino acid propeptide (arbitrium peptide) that is expressed following infection, secreted extracellularly, and post-translationally modified. After the arbitrium peptide accumulates to a specific concentration, the arbitrium peptide is internalized and bound by the AimR receptor, which inhibits the expression of AimX and leads to lysogeny (Fig. C). The Sorek team further determined that when infected bacteria are incubated with the arbitrium peptide from the same phage that infected them, the bacterial growth curve changes due to a shift to a lysogenic cycle (Fig. D). However, when incubated with an arbitrium peptide from a different phage, the bacterial growth curve does not shift, regardless of peptide concentration (Fig. E).

Applications and Advantages

  • Unique system – Effectively induces or shuts off expression of a gene.
  • Standard Chemistry – Uses regular six amino acid peptides, therefore standard synthesis can be used.

Wide Dynamic Range

Over 100 Different Systems

Uniformity Among Systems

Schematic of arbitrium peptide accumulation during phage infection of bacteria. B) Post-infection aimR and aimP expression leading to lysis and AimP accumulation. C) At later stages after infection, lysogeny is preferred due to inhibition of AimX expression. D-E) Growth curves of B. subtillis in the presence of Phage SP Beta with either its corresponding arbitrium peptide (D) or arbitrium peptide from the phi3T phage (E). (Image modified from Erez Z, et al. Nature. [1] 2017 Jan 26;541(7638):488-493. doi: 10.1038/nature21049. Epub 2017 Jan 18)


Erez, Zohar, Ida Steinberger-Levy, Maya Shamir, Shany Doron, Avigail Stokar-Avihail, Yoav Peleg, Sarah Melamed, et al. 2017. “Communication between Viruses Guides Lysis-Lysogeny Decisions.” Nature 541 (7638): 488–93. [2]

Intellectual property status

  • Granted Patent
  • Patent application number :USA Published: Publication Number: 2019-0264213-A1

Related Keywords

  • Biological Sciences
  • Medical Research
  • Biology / Biotechnology
  • Genetic Engineering Technology
  • Micro- and Nanotechnology related to Biological sciences
  • Industrial Products

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support